ABOUT
About this PT-141 digest
An independent, compliance-minded reading of the published research and the regulatory record.
What this site is
Script PT-141 is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature and the regulatory record on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and on the FDA prescribing information.
The "Script" in our name is editorial framing, not a service. It signals the question this digest is built around — what the prescription record actually says, and where it ends — not an offer to write, fill, or facilitate any prescription. Nothing here is a prescription, a referral, or a route to obtain any compound.
Why the regulatory-careful approach
PT-141 is unusual among research peptides because it has a genuine regulatory dossier: an FDA-approved drug (bremelanotide, NDA 210557) for a narrow indication — hypoactive sexual desire disorder in premenopausal women — surrounded by extensive off-label discussion and a separate, unregulated "research-chemical" market. That contrast invites confusion, and confusion is exactly what a careful digest should reduce.
So we lead every claim with its standing. We distinguish the approved indication from off-label and investigational uses, and both from material sold outside the pharmaceutical framework. We report the dose of record from the label without recommending any dose to any individual. And we keep the modest measured effect size and the live scientific debate next to the positive findings, not buried after them.
How we work
Each quantitative claim on this site — every dose, percentage, endpoint, half-life, and trial size — is tied to a numbered citation on the references page, drawn from PubMed-indexed journals, systematic reviews, and the FDA structured product label. Where the literature disagrees, we say so and cite both sides. Where a study has been formally questioned, we flag it. Where a use is off-label or unstudied in a population, we label it rather than imply an approval that does not exist.
The domain modifier in our name is a position we occupy relative to the literature — a reading room organized around the prescription record — not a claim about services we provide. We have no doctors, no pharmacists, and no clinical team.